Chikungunya
ORPHA:324625DiseaseNot applicableAll ages
Фенотипы (HPO)51
Очень частый (80–99%)3
HP:0001945Fever
HP:0002829Arthralgia
HP:0012378Fatigue
Частый (30–79%)15
HP:0000745Diminished motivation
HP:0000988Skin rash
HP:0001369Arthritis
HP:0001386Joint swelling
HP:0001387Joint stiffness
HP:0002315Headache
HP:0003326Myalgia
HP:0005198Stiff interphalangeal joints
HP:0007483Depigmentation/hyperpigmentation of skin
HP:0010741Pedal edema
HP:0010783Erythema
HP:0012733Macule
HP:0030834Shoulder pain
HP:0030839Knee pain
HP:0040186Maculopapular exanthema
Периодический (5–29%)24
HP:0000225Gingival bleeding
HP:0000282Facial edema
HP:0000421Epistaxis
HP:0000613Photophobia
HP:0000716Depression
HP:0000967Petechiae
HP:0000989Pruritus
HP:0000992Cutaneous photosensitivity
HP:0001892Abnormal bleeding
HP:0002013Vomiting
HP:0002014Diarrhea
HP:0007473Crusting erythematous dermatitis
HP:0008066Abnormal blistering of the skin
HP:0009830Peripheral neuropathy
HP:0012219Erythema nodosum
HP:0025143Chills
HP:0025232Bursitis
HP:0025289Cervical lymphadenopathy
HP:0025337Red eye
HP:0032063Ankle joint effusion
HP:0040165Periostitis
HP:0100686Enthesitis
HP:0100769Synovitis
HP:0200037Skin vesicle
Очень редкий (1–4%)9
HP:0001250Seizure
HP:0002383Infectious encephalitis
HP:0002716Lymphadenopathy
HP:0002797Osteolysis
HP:0003401Paresthesia
HP:0003406Peripheral nerve compression
HP:0012185Constrictive median neuropathy
HP:0030880Raynaud phenomenon
HP:0031002Neuritis
Эпидемиология17
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Annual incidence | <1 / 1 000 000 | 0.02 | France | Value and class |
| Point prevalence | Unknown | — | Worldwide | Class only |
| Annual incidence | 1-9 / 1 000 000 | 0.12 | Europe | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.32 | Belgium | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.06 | Finland | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.13 | Germany | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.3 | Italy | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.02 | Latvia | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.35 | Spain | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.16 | Sweden | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.24 | United Kingdom | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.4 | Malta | Value and class |
| Annual incidence | <1 / 1 000 000 | 0.02 | Slovenia | Value and class |
| Annual incidence | <1 / 1 000 000 | — | Greece | Class only |
| Annual incidence | <1 / 1 000 000 | — | Hungary | Class only |
| Annual incidence | <1 / 1 000 000 | — | Ireland | Class only |
| Annual incidence | <1 / 1 000 000 | — | Portugal | Class only |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)